Mn Services Vermogensbeheer B.V. Sells 5,900 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Mn Services Vermogensbeheer B.V. lessened its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 7.2% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 75,600 shares of the medical equipment provider's stock after selling 5,900 shares during the period. Mn Services Vermogensbeheer B.V.'s holdings in Zimmer Biomet were worth $8,556,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Menard Financial Group LLC bought a new stake in Zimmer Biomet during the fourth quarter worth about $30,000. Accredited Wealth Management LLC bought a new stake in Zimmer Biomet during the fourth quarter worth about $36,000. OFI Invest Asset Management bought a new stake in Zimmer Biomet in the fourth quarter valued at approximately $40,000. Dunhill Financial LLC raised its stake in Zimmer Biomet by 86.6% in the fourth quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider's stock valued at $47,000 after buying an additional 206 shares during the period. Finally, SRS Capital Advisors Inc. raised its stake in Zimmer Biomet by 146.9% in the fourth quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider's stock valued at $51,000 after buying an additional 285 shares during the period. Institutional investors own 88.89% of the company's stock.

Analyst Upgrades and Downgrades

ZBH has been the topic of several research analyst reports. JPMorgan Chase & Co. dropped their price objective on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. The Goldman Sachs Group dropped their price objective on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 6th. BTIG Research restated a "buy" rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Stifel Nicolaus set a $115.00 price objective on Zimmer Biomet and gave the company a "buy" rating in a research note on Tuesday, May 6th. Finally, JMP Securities lowered their target price on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $111.53.

Insider Activity

In related news, insider Sang Yi sold 1,000 shares of the firm's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the sale, the insider now owns 20,424 shares of the company's stock, valued at $1,940,280. This trade represents a 4.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 1.39% of the company's stock.

Zimmer Biomet Trading Up 1.0%

Shares of NYSE:ZBH opened at $92.15 on Tuesday. The company has a market capitalization of $18.23 billion, a P/E ratio of 20.71, a P/E/G ratio of 1.95 and a beta of 0.72. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $116.71. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The business's 50 day simple moving average is $96.27 and its 200 day simple moving average is $103.30.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The firm's quarterly revenue was up 1.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.94 earnings per share. On average, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 26th. This represents a $0.96 annualized dividend and a dividend yield of 1.04%. Zimmer Biomet's payout ratio is 21.24%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.